MiRNAs对细胞色素P450s药物代谢酶系调控作用的研究进展

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (11): 1304-1308.

MiRNAs对细胞色素P450s药物代谢酶系调控作用的研究进展

温纯洁, 傅利娟, 吴兰得, 陈旺, 张涛, 周宏灏

重庆医科大学生命科学研究院,重庆 400016

收稿日期:2011-07-05 修回日期:2011-10-06 出版日期:2011-11-26 发布日期:2011-11-29
通讯作者: 周宏灏,男,研究方向:临床药理学和遗传药理学。Tel: 0731-84805380 E-mail: hhzhou2003@163.com
作者简介:温纯洁,女,博士研究生,研究方向:临床药理学和表观遗传药理学。Tel: 0731-84805380 E-mail: wenchunj@sina.com
基金资助:
重庆市教委科学技术研究项目(KJ090306);国家自然科学基金(84402511);重庆市自然科学基金(cstc2011jjA1004);中国博士后基金(2011MS00669)

Development of microRNA-dependent control of cytochrome P450

WEN Chun-jie, FU Li-juan, WU Lan-xiang, CHEN Wang, ZHANG Tao, ZHOU Hong-hao

Institute of Life Sciences,Chongqing Medical University,Chongqing 400016, China

Received:2011-07-05 Revised:2011-10-06 Online:2011-11-26 Published:2011-11-29

摘要/Abstract

摘要： MicroRNAs ( MiRNAs )是一类内源性非编码小分子RNA,一般含有19~25个寡核苷酸,通过与靶mRNA 3'端非翻译区(3'UTR)完全或不完全互补配对,引起mRNA降解或翻译抑制,发挥基因调控作用。MiRNAs在多种生物学过程中都有重要作用,其异常调节会导致各种疾病发生,所以miRNAs被认为可能是新的治疗靶点。MiRNAs在遗传药理学中的作用最近才被研究。化学物质、药物、激素或者是病理状态引起的miRNAs表达的改变可能会导致药物代谢和药物效应的改变。本文主要从miRNAs对细胞色素P450代谢酶和核受体的转录后调控作用作一综述。

关键词: MicroRNA, 细胞色素P450, 遗传药理学, 转录后调控

Abstract: MicroRNAs (miRNAs) are a class of short, non-coding RNAs of 19-25 nucleotides that negatively regulate gene expression by inducing translational inhibition or cleavage of their target mRNAs through binding to the 3′-untranslated regions of target messenger RNAs (mRNAs). Since miRNAs regulate every aspect of cellular function, their dysregulation is associated with a variety of diseases.Therefore, miRNAs are now considered new therapeutic targets.However, the roles of miRNAs in pharmacogenetics have only recently been revealed. The miRNA expression is readily altered by chemicals, drugs, hormones or diseases, and the dysregulation of specifc miRNAs might lead to changes in the drug pharmacokinetics or pharmacodynamics changes. This review describes the current knowledge on the post-transcriptional regulation of cytochrome P450s and nuclear receptors by miRNAs.

Key words: MicroRNA, Cytochrome P450, Pharmacogenetics, Post-transcriptional regulation

中图分类号:

R968

温纯洁, 傅利娟, 吴兰得, 陈旺, 张涛, 周宏灏. MiRNAs对细胞色素P450s药物代谢酶系调控作用的研究进展[J]. 中国临床药理学与治疗学, 2011, 16(11): 1304-1308.

WEN Chun-jie, FU Li-juan, WU Lan-xiang, CHEN Wang, ZHANG Tao, ZHOU Hong-hao. Development of microRNA-dependent control of cytochrome P450[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1304-1308.

参考文献

[1] 周宏灏主编. 遗传药理学[M]. 北京科学出版社, 2001.
[2] Lee RC,Feinbaum RL,Ambros V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell,1993,75(5):843-854.
[3] Reinhart BJ,Slack FJ,Basson M,et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature,2000,403(6772): 901-906.
[4] Johnson SM,Grosshans H,Shingara J,et al. RAS is regulated by the let-7 microRNA family[J]. Cell,2005, 120(5): 635-647.
[5] Griffiths Jones S. The microRNA registry[J]. Nucleic Acids Res,2004,32(Database issue): D109-D 111.
[6] Akao Y,Nakagawa Y,Naoe T. Let-7 microRNA function as a potential growth suppressor in human colon cancer cells[J]. Biol Pharm Bull,2006,29(5):903-906.
[7] 贾音,张毅,孙树汉. MicroRNAs在肿瘤和其它疾病诊断治疗中的应用 [J]. 分子诊断与治疗杂志,2010,2(2):123-127.
[8] Shimada T,Hayes CL,Yamazaki H,et al. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1[J]. Cancer Res,1996,56(13):2979-2984.
[9] Han X,Liehr JG.DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: Hormone-induced free radical damage preceding renal malignancy[J]. Carcinogenesis,1994,15(5):997-1000.
[10] Murray G I,Taylor MC,McFadyen MC,et al. Tumorspeciflc expression of cytochrome P450 CYP1B1[J]. Cancer Res,1997,57(14):3026-3031.
[11] Cheung YL,Kerr AC,McFadyen MC,et al. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours[J]. Cancer Lett,1999,139(2): 199-205.
[12] Tsuchiya Y,Nakajima M,Takagi S,et al. MicroRNA regulates the expression of human cytochrome P450 1B1[J]. Cancer Res,2006,66(18):9090-9098.
[13] Kalscheuer S,Zhang X,Zeng Y,et al. Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone[J]. Carcinogenesis,2008,29(12): 2394-2399.
[14] Deeb KK,Trump DL,Johnson CS. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics[J]. Nat Rev Cancer,2007,7(9):684-700.
[15] Carlberg C,Polly P. Gene regulation by vitamin D3 [J]. Crit Rev Eukaryot Gene Expr,1998,8(1),19-42.
[16] Chen KS,DeLuca HF. Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements[J].Biochim Biophys Acta,1995,1263(1):1-9.
[17] Komagata S,Nakajima M,Takagi S,et al. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b[J]. Mol Pharmacol,2009,76(4):702-709.
[18] Mohri T,Nakajima M,Takagi S, et al. MicroRNA regulates human vitamin D receptor[J]. Int J Cancer,2009,125(6): 1328-1333.
[19] Friedrich M,Axt-Fliedner R,Villena Heinsen C,et al. Analysis of vitamin D-receptor (VDR) and retinoid X-receptor α in breast cancer[J]. Histochem J,2002,34(1/2):35-40.
[20] Tsuchiya Y,Nakajima M,Kyo S,et al. Human CYP1B1 is regulated by estradiol via estrogen receptor[J]. Cancer Res,2004, 64(9): 3119-3125.
[21] Adams BD,Furneaux H,White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines[J]. Mol Endocrinol,2007,21(5):1132-1147.
[22] Zhao JJ,Lin J,Yang H,et al. MicroRNA-221/222 negatively regulates ERα and associates with tamoxifen resistance in breast cancer[J]. J Biol Chem,2008,283(45): 31079-31086.
[23] Xiong J,Yu D,Wei N,et al. An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples[J]. FEBS J,2010,277(7):1684-1694.
[24] Sumida A,Kinoshita K,Fukuda T,et al. Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver[J]. Biochem Biophys Res Commun,1999,262(2):499-503.
[25] Mohri T,Nakajima M,Fukami T,et al. Human CYP2E1 is regulated by miR-378[J]. Biochem Pharmacol,2010,79(7): 1045-1052.
[26] Takagi S, Nakajima M, Mohri T,et al.Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4[J]. J Biol Chem,2008,283(15):9674-9680.
[27] Pan YZ,Gao W,Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting[J]. Drug Metab Dispos,2009,37(10): 2112-2117.
[28] Gonzalez FJ. Regulation of hepatocyte nuclear factor 4α-mediated transcription[J]. Drug Metab Pharmacokinet,2008, 23(1):2-7.
[29] Takagi S,Nakajima M,Kida K,et al. MicroRNAs regulate human hepatocyte nuclear factor 4α, modulating the expression of metabolic enzymes and cell cycle[J]. J Biol Chem,2010,285(7):4415-4422.
[30] Rukov JL,Shomron N. MicroRNA pharmacogenomics:Post-transcriptional regulation of drug response[J]. Trends Mol Med,2011,17(8):412-423.
[31] Nakai K,Tsuboi J,Okabavashi H, et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients[J]. Pharmacogenomics,2007,8(7):713-719.
[32] Shomron N. MicroRNAs and pharmacogenomics[J]. Pharmacogenomics ,2010,11(5): 629-632
[33] Hebert SS,Horre K,Nicolai L,et al. MicroRNA regulation of Alzheimer's amyloid precursor protein expression[J]. Neurobiol Dis,2009,33(3):422-428.
[34] Roberson ED,Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease[J]. Science, 2006,314(5800):781-784.
[35] Lanford RE,Hildebrandt-Eriksen ES,Petri A,et al.Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection[J]. Science,2010,327(5962):198-201.
[36] Gurwitz D,Motulsky AG. Drug reactions, enzymes, and biochemical genetics: 50 years later[J]. Pharmacogenomics,2007,8(11):1479-1484.
[37] 沈杰,谢海棠,刘昭前. 遗传药理学与高血压药物治疗进展[J].中国临床药理学与治疗学,2010,15(6):705-714.